Rivastigmine
Product Images NDC 51956-0002

21 FDA label images from Zydus Lifesciences Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 51956-0002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 01)

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 01)
Chemical structure of Rivastigmine showing its molecular framework with carbon, hydrogen, nitrogen, and oxygen atoms arranged including aromatic ring and ester functional groups, as represented in a standard skeletal formula.*
FDA Label Image

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 02)

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 02)
An illustration showing a cross-sectional diagram labeled with four distinct layers, named Layer 1 through Layer 4, arranged vertically from top to bottom. Each layer is visually differentiated by unique patterns.*
FDA Label Image

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 03)

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 03)
Pharmacokinetic line graph showing Rivastigmine plasma concentration (ng/mL) over 24 hours at three different dosages: 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The graph includes error bars indicating variability at each time point for sample sizes of 19 to 22 subjects.*
FDA Label Image

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 04)

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 04)
A line chart depicting the least square means (+/- SEM) change in ADAS-Cog rating from baseline over 24 weeks of treatment. Four groups are shown: 17.4 mg/24 hours, 9.5 mg/24 hours, Capsules 6 mg BID, and Placebo. The y-axis indicates clinical improvement (negative values) and clinical decline (positive values) with improvement increasing over time for the 17.4 mg/24 hours group and decline for the placebo group.*
FDA Label Image

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 05)

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 05)
A bar chart showing the distribution of ADCS-CGIC ratings for patients administered Rivastigmine at doses of 17.4 mg/24 hours, 9.5 mg/24 hours, capsules 6 mg BID, and placebo. The y-axis represents the percentage of patients, while the x-axis categorizes ratings from markedly improved to markedly worse. The chart compares patient outcomes across different Rivastigmine treatments and placebo.*
FDA Label Image

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 06)

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 06)
A line graph showing the change from baseline in ADCS-IADL scores over 48 weeks of treatment with Rivastigmine Transdermal Systems at doses of 13.3 mg/24 hr and 9.5 mg/24 hr. The graph depicts clinical improvement or decline, with the 13.3 mg/24 hr dose maintaining higher scores and less clinical decline compared to the 9.5 mg/24 hr dose. Statistical significance is indicated at several time points for the 13.3 mg dose versus the 9.5 mg dose.*
FDA Label Image

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 07)

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 07)
A line graph depicting ADAS-Cog change from baseline over 48 weeks of treatment with Rivastigmine Transdermal System at doses of 13.3 mg/24 hr and 9.5 mg/24 hr. The y-axis shows change in cognition from clinical improvement to clinical decline, and the x-axis shows weeks of treatment. The 13.3 mg dose shows less clinical decline compared to the 9.5 mg dose over time, with statistical significance indicated at week 24.*
FDA Label Image

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 08)

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 08)
A line graph comparing the least squares mean change with standard errors over 24 weeks of treatment for two Rivastigmine transdermal systems: 13.3 mg/24 hr and 4.6 mg/24 hr. The y-axis shows LS mean change with error bars, and the x-axis shows weeks of treatment. Data points indicate clinical improvement or decline with statistical significance noted for weeks 16 and 24.*
FDA Label Image

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 09)

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 09)
A line graph comparing the least squares mean change with standard errors over 24 weeks of treatment for Rivastigmine Transdermal System at doses of 13.3 mg/24 hr and 4.6 mg/24 hr. The y-axis measures LS mean change ± standard errors, indicating clinical improvement or decline. Data points at 8, 16, and 24 weeks show differences in clinical outcomes with p-values and confidence intervals noted for statistical significance.*
FDA Label Image

Figure A (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 10)

Figure A (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 10)
Diagram showing the components of the Rivastigmine Transdermal System by Zydus Lifesciences Limited. It illustrates the pouch packaging containing the transdermal system, the system itself with protective liners on both sides, and a detailed view highlighting the adhesive with medicine and outside backing of the patch.*
FDA Label Image

Figure B (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 11)

Figure B (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 11)
An instructional diagram showing possible application sites for Rivastigmine patches by Zydus Lifesciences Limited. It illustrates four body areas with shaded squares: left or right upper arm (side view), left or right side of the chest (front view), left or right upper back (back view), and left or right lower back (back view), indicating where to place the patch.*
FDA Label Image

Figure C (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 12)

Figure C (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 12)
An illustration showing a hand holding a Rivastigmine Transdermal System package, positioned next to scissors. The package indicates it is for transdermal use only and contains one system. The illustration suggests using scissors to open the package along a marked line.*
FDA Label Image

Figure D (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 13)

Figure D (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 13)
An instructional diagram showing two hands holding and peeling open a small blister pack or strip containing one round tablet. The image illustrates the process of removing the tablet from its protective packaging, indicated by arrows suggesting outward peeling motion.*
FDA Label Image

Figure E (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 14)

Figure E (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 14)
An instructional diagram showing two hands handling a transdermal system patch. The image highlights protective liners covering the adhesive sticky surface of the patch, indicating their removal prior to application.*
FDA Label Image

Figure F (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 15)

Figure F (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 15)
An instructional illustration showing a person applying a patch to the upper back or shoulder area. One hand is peeling the protective backing from the patch while the other hand is pressing it onto the skin. This image is likely related to applying a transdermal medication patch.*
FDA Label Image

Figure G (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 16)

Figure G (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 16)
Black and white line drawing showing a person's upper back and a hand placed on the left shoulder blade area. The illustration appears to demonstrate a position or technique involving the back and shoulder region.*
FDA Label Image

Figure H (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 17)

Figure H (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 17)
An instructional illustration showing the application of a patch on the upper chest area. One hand is holding the patch while the other is pressing it onto the skin, demonstrating a circular motion to secure the patch in place. This likely relates to the use instructions for Rivastigmine transdermal patches.*
FDA Label Image

Figure I (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 18)

Figure I (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 18)
Instructional illustration for disposing of a Rivastigmine transdermal system patch. Steps show folding the sticky sides of the patch together, sliding the folded patch into an empty pouch labeled 'Rivastigmine Transdermal System' by Zydus Lifesciences Limited, and placing the pouch in the trash with a reminder to keep it away from children and pets.*
FDA Label Image

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 19)

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 19)
Label for Rivastigmine Transdermal System delivering 4.6 mg/24 hours, intended for transdermal use only. The package contains 30 systems and is labeled Rx only. Manufactured by Zydus Pharmaceuticals USA, a division of Zydus Lifesciences Limited.*
FDA Label Image

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 20)

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 20)
Rivastigmine Transdermal System patch delivering 9.5 mg per 24 hours. Packaging label indicates prescription use only, for transdermal application, containing 30 systems. Labeler is Zydus Lifesciences Limited (Zydus Pharmaceuticals USA).*
FDA Label Image

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 21)

Rivastigmine Transdermal System (8ce6f8ae C5f5 4731 8efb 9a8c3d52942f 21)
Label for Rivastigmine Transdermal System delivering 13.3 mg per 24 hours. The label indicates it is for transdermal use only, contains 30 systems, and is Rx only. The product is labeled by Zydus Pharmaceuticals USA, a division of Zydus Lifesciences Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.